Bio-Techne announced that the General Services Administration (GSA) has awarded an unlimited 10-year reimbursement contract to its Exosome Diagnostics laboratory, covering the ExoDx Prostate (EPI) test for men, according to a company news release.
The contract makes the test available to more than 140 government entities including the Veterans Health Administration, the military branches of service and Senate and House of Representatives.
The liquid biopsy test recently received FDA Breakthrough Designation and is included in the National Comprehensive Cancer Network (NCCN) guidelines for early detection in men for both initial and repeat biopsy.
The EPI test is a risk assessment tool that helps physicians and patients determine if a prostate biopsy is needed when a PSA test result is ambiguous, the company said.
